Both the nine-valent vaccine and the quadrivalent vaccine can be used to prevent cervical cancer caused by human papillomavirus (HPV) infection, but there are still major differences between the two, in terms of vaccination population, prevention scope and price. 1. vaccination population: the nine-valent vaccine is suitable for women aged 16-26, while the quadrivalent vaccine is suitable for women aged 20-45. The quadrivalent vaccine covers a wider range of people, relatively speaking; 2. Scope of prevention: the nine-valent vaccine can prevent a total of 9 types of HPV infections, 6, 11, 16, 18, 31, 33, 45, 52 and 58, while the quadrivalent vaccine can prevent a total of 4 types of HPV infections, 6, 11, 16 and 18. Price: There are different prices for the nine-valent vaccine and the quadrivalent vaccine in different areas of the market, and usually the price of the nine-valent vaccine is higher than the quadrivalent vaccine. After the nine-valent vaccine or quadrivalent vaccine, headache, fever, or redness and swelling at the injection site may occur, which is usually normal and can be relieved by itself in a short period of time. If the symptoms are serious, such as nausea, vomiting, diarrhea, etc., are more intense and do not relieve, go to the hospital for treatment in time.